Thyroidectomy

Sernova Presents Compelling New Data on the Cell Pouch System™ as a Promising Treatment for Post-Operative Hypothyroidism at the 2023 American Thyroid Association Annual Meeting

Retrieved on: 
Friday, September 29, 2023
Thyroid hormones, TSH, American Thyroid Association, Histology, Depression, FSE, ATA, FT4, Quality of life, PSH, Hypothyroidism, Weight gain, Thyroidectomy, Triiodothyronine, Patient, Cell, Annual general meeting, TSX, Poster, Memory, Fatigue, Thyroid, Medical imaging, Pharmaceutical industry

Thyroid stimulating hormone (TSH) levels had a significant peak immediately after thyroidectomy, with a gradual decline observed starting five weeks after the re-implantation of thyroid glands.

Key Points: 
  • Thyroid stimulating hormone (TSH) levels had a significant peak immediately after thyroidectomy, with a gradual decline observed starting five weeks after the re-implantation of thyroid glands.
  • Newly reported radio-isotope uptake imaging and histology assessments confirmed the presence of healthy and functional thyroid tissues within the Cell Pouch six months following re-implantation.
  • “With Sernova’s Cell Pouch System, we aim to improve quality of life with a treatment for post-operative hypothyroidism.
  • These new data replicate a human clinical scenario in which thyroid tissue is reimplanted into the patient, via the Cell Pouch, leading to the restoration of normal thyroid function.

Sernova Responds to Dissident Shareholders’ Misleading Statements and Provides Corporate Updates

Retrieved on: 
Thursday, April 6, 2023
TSX Venture Exchange, Telephone, Optimization, Thyroid, HAS, Patient, ILC, Cell, American Diabetes Association, ADA, University, FSE, Dissident, Type 1 diabetes, Research, TSX, IND, Exercise, IPSC, T1D, PSH, Transplant, Thyroidectomy, Glycated hemoglobin, Partnership, Clinical trial, AGM, Hypothyroidism, Immunosuppression, Functional testing, Security (finance), Pharmaceutical industry, Vaccine, Dentistry, Evotec

The two individuals nominated by the dissident shareholder group elected not to participate in the interview process nor did they meet with Sernova’s board.

Key Points: 
  • The two individuals nominated by the dissident shareholder group elected not to participate in the interview process nor did they meet with Sernova’s board.
  • The current board members are well positioned to build on the progress the Company has made to date and take Sernova to its next stage of development as outlined under the Corporate Updates below.
  • The Company is providing the following updates to keep shareholders abreast of developments and work that will create value for shareholders.
  • Sernova shareholders who have any questions or require assistance with voting may contact Sernova’s proxy solicitation agent and shareholder communications advisor:

Sernova Announces Advancements with its Novel Cell Pouch System™ to Preserve Thyroid Function Following Total Thyroidectomy

Retrieved on: 
Monday, January 30, 2023
Cell, PLOS One, Weight gain, ST, Triiodothyronine, MD, Thyroid, Constipation, North Central Cancer Treatment Group, Synthetic control method, PMID, Amnesia, TSX, Thyroid hormones, JAMA Otolaryngology–Head & Neck Surgery, Survival, FACS, PSH, Bachelor of Science, Depression, FRCSC, University, Institute for Quality and Efficiency in Health Care, Patient, The Control Group, Hypothyroidism, FSE, Faculty, Thyroidectomy, Medical school, Quality, Haemophilia, Control Group, Metabolism, Dentistry, Pharmaceutical industry, Medicine, T4

The study was conducted in a pre-clinical animal model whereby the Cell Pouch was pre-implanted for several weeks prior to each subject undergoing total thyroidectomy.

Key Points: 
  • The study was conducted in a pre-clinical animal model whereby the Cell Pouch was pre-implanted for several weeks prior to each subject undergoing total thyroidectomy.
  • The thyroid gland of each Treatment Group subject was removed, prepared with minimal manipulation, and transplanted into the pre-implanted Cell Pouch.
  • Following thyroidectomy in the Treatment Group, the T3 and T4 levels fell initially but subsequently recovered to normal or near-normal levels following thyroid transplant into the Cell Pouch.
  • Control Group subjects received the Cell Pouch implant and underwent total thyroidectomy but did not receive a thyroid transplant.

EQS-News: Sernova Announces Advancements with its Novel Cell Pouch System(TM) to Preserve Thyroid Function Following Total Thyroidectomy

Retrieved on: 
Thursday, February 2, 2023
Constipation, Institute for Quality and Efficiency in Health Care, Thyroid, ST, University, Thyroidectomy, Amnesia, Quality, Medical school, Bachelor of Science, Haemophilia, FSE, Depression, TSX, MD, FRCSC, PMID, Control Group, Weight gain, Survival, PLOS One, Metabolism, Patient, Hypothyroidism, JAMA Otolaryngology–Head & Neck Surgery, North Central Cancer Treatment Group, FACS, Triiodothyronine, Faculty, The Control Group, Thyroid hormones, Synthetic control method, PSH, Cell, Dentistry, Pharmaceutical industry, Medicine, T4

The study was conducted in a pre-clinical animal model whereby the Cell Pouch was pre-implanted for several weeks prior to each subject undergoing total thyroidectomy.

Key Points: 
  • The study was conducted in a pre-clinical animal model whereby the Cell Pouch was pre-implanted for several weeks prior to each subject undergoing total thyroidectomy.
  • The thyroid gland of each Treatment Group subject was removed, prepared with minimal manipulation, and transplanted into the pre-implanted Cell Pouch.
  • Following thyroidectomy in the Treatment Group, the T3 and T4 levels fell initially but subsequently recovered to normal or near-normal levels following thyroid transplant into the Cell Pouch.
  • Control Group subjects received the Cell Pouch implant and underwent total thyroidectomy but did not receive a thyroid transplant.

Olympus Launches THUNDERBEAT Energy Device for Open Surgery

Retrieved on: 
Wednesday, September 28, 2022
Pyronia, Olympus, Efficiency, Olympus Corporation, Risk, Advanced Energy, Patient, Dissection, Thyroidectomy, Quality of life, General manager, Hospital, Multimedia, View, Bipolar, Dentistry, Medical device

TOKYO and CENTER VALLEY, Pa., Sept. 28, 2022 /PRNewswire/ -- Olympus Corporation (Olympus), a global medtech company committed to making people's lives healthier, safer, and more fulfilling, today announced the release of the THUNDERBEAT Open Fine Jaw Type X surgical energy devices for open surgery.

Key Points: 
  • TOKYO and CENTER VALLEY, Pa., Sept. 28, 2022 /PRNewswire/ -- Olympus Corporation (Olympus), a global medtech company committed to making people's lives healthier, safer, and more fulfilling, today announced the release of the THUNDERBEAT Open Fine Jaw Type X surgical energy devices for open surgery.
  • With a new thermal shield, the THUNDERBEAT Open Fine Jaw Type X surgical energy device is designed to support safer procedures.iThe device is available commercially in Japan.
  • This device is part of Olympus' THUNDERBEAT portfolio of hybrid energy devices that deliver both ultrasonic and bipolar energy simultaneously for tissue management, including hemostatic cutting and dissection, in laparoscopic surgery and open surgery.
  • The THUNDERBEAT Open Fine Jaw Type X device is manufactured by Olympus Medical Systems Corporation.

Olympus Launches THUNDERBEAT Energy Device for Open Surgery

Retrieved on: 
Wednesday, September 28, 2022
Olympus, Efficiency, Twitter, Risk, Advanced Energy, Patient, Dissection, Thyroidectomy, Quality of life, General manager, Hospital, Bipolar, Dentistry, Medical device

With a new thermal shield, the THUNDERBEAT Open Fine Jaw Type X surgical energy device is designed to support safer procedures.

Key Points: 
  • With a new thermal shield, the THUNDERBEAT Open Fine Jaw Type X surgical energy device is designed to support safer procedures.
  • This device is part of Olympus' THUNDERBEAT portfolio of hybrid energy devices that deliver both ultrasonic and bipolar energy simultaneously for tissue management, including hemostatic cutting and dissection, in laparoscopic surgery and open surgery.
  • The THUNDERBEAT(TM) Open Fine Jaw Type X device is a single use hybrid ultrasonic and bipolar electrosurgical instrument intended for use in open surgery.
  • The THUNDERBEAT Open Fine Jaw Type X device is manufactured by Olympus Medical Systems Corporation.

Thyroid Cancer Drugs Global Market Research Report 2022: Focus on Ipilimumab, Cabozantinib-S-Malate, Caprelsa (Vandetanib), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Nivolumab, Vandetanib - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 30, 2022
Pharmaceutical, Health, Oncology, FDA, Doxorubicin, Iodine, Patient, Goitre, Protein, GlaxoSmithKline, BRAF, Tissue, American Cancer Society, AstraZeneca, Trametinib, Death, Abbott, Man, Medullary thyroid cancer, Growth, Cancer, MTC, MEK, Disease, API, Thyroid cancer, THS, Baxter International, Cabozantinib, Woman, Drug resistance, Thyroidectomy, Food, Teva, Shanda, Radiation, Nivolumab, Survival, Ipilimumab, History of the Food and Drug Administration, Thyroid lymphoma, Hospital, Pharmaceutical industry, Medical imaging, Dietary supplement, Vandetanib

The "Thyroid Cancer Drugs Global Market Report 2022, Drug Type, End Users, Type" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Thyroid Cancer Drugs Global Market Report 2022, Drug Type, End Users, Type" report has been added to ResearchAndMarkets.com's offering.
  • The thyroid cancer drugs market consists of sales of drugs that are used to treat thyroid cancer.
  • Increasing incidences of thyroid cancer, especially in women is driving the thyroid cancer drugs market.
  • Increasing use of targeted therapies for the treatment of thyroid cancer is acting as a restraint on the thyroid cancer drugs market.

New Study from StrategyR Highlights a $3.7 Billion Global Market for Ultrasonic Scalpels by 2026

Retrieved on: 
Wednesday, March 23, 2022
Adoption, Ultrasound, CAGR, Appendectomy, Tonsillectomy, Players, ENT, Investment, Marketing, Growth, Urology, Uterine fibroid, General surgery, Research, Culdocentesis, Forecasting, Thyroidectomy, Bleeding, Tissue, Intelligence, Stryker Corporation, Prevalence, Joint, Gynaecology, Surgeon, GIA, COVID-19, Olympus Corporation, Endometriosis, Attention, VDW, Spine, SAN, Medtronic, Scalpel, Pain, Johnson & Johnson, Pharmaceutical industry, Others

SAN FRANCISCO, March 23, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Ultrasonic Scalpels - Global Market Trajectory & Analytics" .

Key Points: 
  • SAN FRANCISCO, March 23, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Ultrasonic Scalpels - Global Market Trajectory & Analytics" .
  • Previews provide deep insider access to business trends; competitive brands; domain expert profiles; and market data templates and much more.
  • This segment currently accounts for a 29.8% share of the global Ultrasonic Scalpels market.
  • Global Industry Analysts, Inc., ( www.strategyr.com ) is a renowned market research publisher the world`s only influencer driven market research company.

Interpace Diagnostics Announces US Patent Approval for Patent Application No. 11,118, 231 B2 Titled: microRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms

Retrieved on: 
Thursday, October 21, 2021
Safety, Pancreatic cancer, EBITDA, Securities Act of 1933, Diagnosis, Technology, Prognosis, Intellectual, Cancer, Goal, Drug development, PTO, MBA, Security (finance), U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, Thyroid cancer, MicroRNA, Esophageal cancer, Terminology, Sumathi Best Television Current Reporting Award, RNA, Risk, Franciscan Ceramics, Patent, United States Patent and Trademark Office, Pancreatic cyst, Protein, Company, Thyroidectomy, Pharma, COVID-19, Intellectual property, CEP, Lung cancer, Health, GLOBE, Securities Exchange Act of 1934, Physician, Medical device

MicroRNAs are small, non-coding RNAs that bind to messenger RNA and regulate expression of proteins involved in human cancers, including thyroid cancer.

Key Points: 
  • MicroRNAs are small, non-coding RNAs that bind to messenger RNA and regulate expression of proteins involved in human cancers, including thyroid cancer.
  • ThyraMIR, our micro-RNA classifier, is designed to work in concert with Interpaces NGS based ThyGeNEXT test to risk stratify indeterminate Thyroid nodules.
  • By measuring the expression levels of 10 microRNAs, ThyraMIR, in combination with ThyGeNEXT provide actionable rule-in and rule-out results, reducing unnecessary Thyroidectomy surgeries and improving patient care.
  • Alidad Mireskandari, Ph.D., MBA, Chief Development Officer of Interpace Biosciences stated, We are pleased to announce the approval of this patent by the US PTO.

Children Requiring Thyroid Surgery Experience Better Outcomes At High-Volume Surgery Centers

Retrieved on: 
Thursday, April 4, 2019
Thyroid disease, Medicine, Glands, Organ systems, Thyroidectomy, Thyroid, Pediatrics, Specialty, Papillary thyroid cancer, Thyroid cancer

The findings underscore how a highly experienced clinical team can make a big difference when it comes to patient outcomes.

Key Points: 
  • The findings underscore how a highly experienced clinical team can make a big difference when it comes to patient outcomes.
  • Since thyroid disease is less common in children than adults, pediatric surgery specialists often have less experience in managing thyroid disease.
  • The study team reviewed medical records of 464 pediatric patients undergoing thyroid surgery at CHOP between 2009 and 2017.
  • Baumgarten et al, "Surgical management of pediatric thyroid disease: Complication rates after thyroidectomy at the Children's Hospital of Philadelphia high-volume Pediatric Thyroid Center."